

Abstract of the Disclosure

The invention is directed to methods of treating diabetes by administering p38 mitogen activated protein kinase inhibitors. The invention is also directed to methods of decreasing blood glucose level in diabetes patients by administering p38 mitogen activated protein kinase inhibitors.